Assembly systems and automation equipment for precision manufacturing
Mikron Automation designs and manufactures custom assembly systems for pharmaceutical, medtech, and automotive production lines. The tech stack (AutoCAD, Inventor, Cognex vision, Allen-Bradley controls, SAP) reflects a capital-equipment builder with embedded quality and process automation. Recent hiring is concentrated in engineering and manufacturing — currently recruiting mid-level and lead engineers in the US — aligned with their core challenge of scaling production volume and closing larger orders.
Mikron Automation is a division of the Swiss Mikron Group, a public industrial automation company founded in 1918. The company manufactures and installs custom assembly and testing systems for customers in pharmaceuticals, medical devices, automotive, electrical, industrial, and consumer goods. With over 1,000 employees across sites in Switzerland, the US, Singapore, China, and Lithuania, Mikron has delivered more than 4,200 systems worldwide and executes more than 100 projects annually. The business model combines capital equipment sales with lifelong service and support contracts.
Mikron Automation designs and installs custom assembly and testing systems for pharmaceutical, medtech, automotive, and industrial production. The company has delivered over 4,200 systems globally and executes more than 100 projects per year.
Engineering and design: AutoCAD, Inventor, Mastercam. Vision and controls: Cognex, Keyence, Allen-Bradley, HMI. Enterprise: Salesforce, SAP, Microsoft Project. Development: C#, Blazor.
Other companies in the same industry, closest in size
Mikron Automation's technology stack, projects, and hiring signals are inferred from public hiring and company data — career pages, public listings, and company web presence — then clustered and de-duplicated. Figures are estimates that refresh over time. Read our full methodology →
This is not an official vendor or customer list. It is a technology-adoption signal inferred from public data, intended for B2B research.